Is the prognosis of non‐hypertensive, COVID‐19 patients treated with renin–angiotensin–aldosterone system inhibitors more uncertain?

Is the prognosis of non‐hypertensive, COVID‐19 patients treated with renin–angiotensin–aldosterone system inhibitors more uncertain?

Abstract Previous studies suggested that ongoing treatment with renin–angiotensin–aldosterone system (RAAS) inhibitor drugs may alter the course of SARS‐CoV‐2 infection and promote the development of more severe forms of the disease. The authors conducted a comparative, observational study to retros...

Full description

Bibliographic Details
Main Authors: Juan José García Martínez, Hannah Wozniak, Pauline Salamin, Raphaël Giraud, Christophe Le Terrier, Karim Bendjelid
Format: Article
Language:English
Published: Wiley 2022-11-01
Series:Physiological Reports
Subjects:
ACE2
COVID‐19
hypertension
ICU
renin–angiotensin–aldosterone
Online Access:https://doi.org/10.14814/phy2.15512

Internet

https://doi.org/10.14814/phy2.15512

Similar Items